Taken together, our study showed that Tim‐3 was an independent risk factor at the level of leukemic cells and LSCs in AML patients, and high expression of Tim‐3 in leukemic blast represented LSC signaling and suppression of immune response. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.